These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 25654813)

  • 1. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
    Pal A; Sarkar N; Saha D; Guha SK; Saha B; Chakrabarti S; Chakravarty R
    Antivir Ther; 2015; 20(5):545-54. PubMed ID: 25654813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
    Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
    Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
    Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
    AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
    Archampong TN; Boyce CL; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Blackard JT; Kwara A
    Antivir Ther; 2017; 22(1):13-20. PubMed ID: 27167598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.
    Gu L; Han Y; Li Y; Zhu T; Song X; Huang Y; Yang F; Guan S; Xie J; Gohda J; Hosoya N; Kawana-Tachikawa A; Liu W; Gao GF; Iwamoto A; Li T; Ishida T
    PLoS One; 2015; 10(8):e0134539. PubMed ID: 26288093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
    Kouanfack C; Aghokeng AF; Mondain AM; Bourgeois A; Kenfack A; Mpoudi-Ngolé E; Ducos J; Delaporte E; Laurent C
    Antivir Ther; 2012; 17(2):321-6. PubMed ID: 22290198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
    Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
    HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
    Belyhun Y; Maier M; Liebert UG
    Antivir Ther; 2017; 22(2):97-111. PubMed ID: 27354181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.
    Coffin CS; Osiowy C; Myers RP; Gill MJ
    J Clin Virol; 2013 Jun; 57(2):103-8. PubMed ID: 23465393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
    Santos EA; Sucupira MV; Arabe J; Gomes SA
    BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
    Mendes-Correa MC; Pinho JR; Locarnini S; Yuen L; Sitnik R; Santana RA; Gomes-Gouvêa MS; Leite OM; Martins LG; Silva MH; Gianini RJ; Uip DE
    J Med Virol; 2010 Sep; 82(9):1481-8. PubMed ID: 20648600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
    Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
    AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain.
    Tuma P; Pineda JA; Labarga P; Vidal F; Rodriguez C; Poveda E; Santos J; Gonzalez-García J; Sobrino P; Tural C; Soriano V;
    Antivir Ther; 2011; 16(4):585-9. PubMed ID: 21685546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C.
    Hsieh TH; Tseng TC; Liu CJ; Lai MY; Chen PJ; Hsieh HL; Chen DS; Kao JH
    Antivir Ther; 2009; 14(8):1157-63. PubMed ID: 20032545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.